ClinicalTrials.gg
RecruitingNCT06692075ECLS-OHCAUpdated Nov 9, 2026

Emergency Total ECLS vs Standard ACLS With ECMO Bailout for Survival in Refractory OHCA

An interventional study of extracorporeal life support and standard ACLS in Out-of-hospital Cardiac Arrest (OHCA), sponsored by Taipei Medical University Shuang Ho Hospital. Recruiting at 2 sites in Taiwan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Taipei Medical University Shuang Ho Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Nov 9, 2026Now RecruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Out-of-Hospital Cardiac Arrest with a site in Taiwan — 9 open to participants now, 10 under way, none of them phase 3. Out-of-Hospital Cardiac Arrest · Taiwan.

Planned enrollment
5th of 13
332 · median 132
Started
2024
with 3 others
No phase
12 of 23
5 open now
Registered
16th of 23
by date
Lead sponsor
1 of 23
Taipei Medical University Shuang Ho Hospital

Among the 23 studies in Out-of-Hospital Cardiac Arrest with a site in Taiwan, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2024, is one of 12 with no phase, and was the 16th registered.

Out-of-Hospital Cardiac Arrest

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

Browse Out-of-Hospital Cardiac Arrest studies →

Open to participants now

9 of the 23 studies in Out-of-Hospital Cardiac Arrest with a site in Taiwan are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Out-of-Hospital Cardiac Arrest with a site in Taiwan, or all of them as a file.
02

Study summary

The goal of the clinical trial is to learn if early extracorporeal life support ( ECLS ) will save more out-of-hospital cardiac arrest ( OHCA ) patients with good neurological outcome. It will also learn if emergency ECLS is safe in the OHCA rescue. Researchers aim to investigate if emergency total ECLS is better than standard advanced cardiac life support ( ACLS ) first, followed by bailout ECMO if required, for survival with favorable neurological outcome in OHCA patients. Participants meeting criteria of OHCA with witness, bystander CPR, shockable initial rhythm with repeated defibrillation, and transport time less than 30 min will be compared between total ECLS versus standard ACLS first with bailout ECMO protocols. All participants will receive emergency interventional coronary revascularization , intensive care unit therapy , cardiac ward care and up to 180 days of clinical follow up after survival .

Read the detailed description

Out-of-hospital cardiac arrest ( OHCA ) is a highly lethal emergency, unless return of spontaneous circulation ( ROSC ) is timely achieved by efficient and effective resuscitation. Nevertheless, despite advanced cardiopulmonary resuscitation ( CPR ) with mechanical chest compression, assisted ventilation and automatic external defibrillation, the survival of OHCA patients remains below 10%. Extracorporeal membranous oxygenation ( ECMO ) facilitated life support ( ECLS ) could help hemodynamic stability and improve significantly the survival of refractory OHCA to 25-40 %. On the other hand, the precise role and timing of the ECLS during the emergency management of OHCA remains largely unestablished.

In the present study, we hypothesized that emergency total ECLS is superior to standard ACLS with ECMO bailout for survival with favorable neurological outcome in refractory out-of-hospital cardiac arrest. All OHCA patients meeting the including criteria, i.e. age 18-75 years, witnessed cardiac arrest with bystander CPR, initial shockable rhythm as ventricular fibrillation or pulseless ventricular tachycardia ( VF/pVT ), repeated defibrillation shocks and escorted transportation within 30 minutes from 119 call to arriving emergency department ( ED ) in the hospital would be recruited. Eligible patients will be consecutively randomized at ED in 1:1 ratio, stratified by hospitals, into emergency total ECLS group and standard ACLS with ECMO bailout group. Informed consent is waived in the life-threatening emergency condition. For emergency total ECLS group, OHCA patients will receive early implantation and initiation of ECMO circulation within 15 minutes after randomization or up to 45 minutes after 119 call. For standard ACLS with ECMO bailout group, OHCA patients will receive standard ACLS for at least 45 minutes after collapse or 119 call or at least 15 minutes after ED arrival before calling for bailout ECMO if required. Following return of spontaneous systemic circulation (ROSC) or depending on ECMO circulation, both groups would be transferred to brain and chest computer tomography screening, emergency coronary revascularization intervention and subsequent intensive cardiac care with targeted hypothermia management. Survivals will be treated with guideline directed medical therapy for reduced ejection fraction heart failure and/or implantable cardioverter-defibrillator implantation for prevention of recurrent VT/VF in wards. All survivals will be followed up for medical and neurological status at 30 days, 90 days and 180 days after discharge.

Primary endpoint is survival with favorable neurological outcome at 30 days. Secondary endpoints are survival to discharge with favorable neurological outcome, survival with favorable neurological outcome at 180 days, total duration of cardiopulmonary resuscitation ( CPR ), total duration of mechanical ventilation, total duration of intensive care unit stay, total duration of hospitalization. Safety endpoints will be incidence of serious adverse events related to prolonged CPR, prolonged ischemia, and ECMO systemic perfusion and coronary reperfusion.

The number of subjects to be enrolled according to the primary endpoint of 30 days survival with favorable neurological outcome. With a power of 80%, accepting the level of statistical significance at alpha= 0.05 and based on two-sided Chi-Square test, we estimated 166 participants per arm are needed. This is based on the 30% success rate and 15% success rate of 30-day survival with good neurological outcome of emergency total ECLS intervention and standard ACLS with bailout ECMO (if required) intervention, according to previous trials, plus a 10% drop out rate. Based on two-tailed test, p less than 0.05 is considered statistical significance. If interim analysis is deemed necessary, the significance level will be adjusted accordingly using Bonferroni method. Because of no interim analysis and no stopping point in ITT protocol, there is no criteria for premature termination of the trial. The missing data of the primary and secondary efficacy outcomes will be considered as failure for ITT analysis. Last observations carry forward method will be adapted for the missing data of repeated measurements. The data record will be monitored and audited by the Institutional Review Board of the TMU Shuangho hospital as well as the Data and Safety Monitoring Plan committee.

03

Conditions studied

  • Out-of-hospital Cardiac Arrest (OHCA)

Keywords

  • out-of-hospital cardiac arrest
  • extracorporeal life support
  • advanced cardiac life support
  • sudden death
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. adults aged 18-75 years old
  2. witnessed cardiac arrest with bystander CPR
  3. initial shockable rhythm as ventricular fibrillation or pulseless ventricular tachycardia ( VF/pVT )
  4. repeated defibrillation shocks ( more than 2 ) by external defibrillator
  5. estimated transportation time from 119 call to arrival at emergency service less than 30 minutes.

Exclusion criteria

Exclusion Criteria:

  1. age less than 18 years or more than 75 years old
  2. non-shockable initial rhythm, i.e. pulseless electrical activity or asystole
  3. acute aortic dissection
  4. acute massive pulmonary embolism
  5. intracerebral hemorrhage
  6. major trauma due to blunt, penetrating or burn injury
  7. severe peripheral artery occlusion disease
  8. known pregnancy
  9. suicide, illicit drug overdose or intoxication
  10. known pre-arrest modified Rankin score ( mRS ) more than 3 or cerebral performance category scale ( CPC ) more than 2
  11. severe concomitant with expected less than 1 year
  12. signed and effective do-not-resuscitation ( DNR ) order
  13. absolute to emergency coronary angiography, including known anaphylactic reaction to angiographic contrast media, acute gastrointestinal bleeding or internal bleeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
332 participants (estimated)

Study arms

  • Active comparator
    Total ECLS in refractory OHCA

    Emergency total extracorporeal life support ( ECLS ) in cardiopulmonary resuscitation of OHCA patients with refractory ventricular fibrillation or pulseless ventricular tachycardia

    Procedure: extracorporeal life support

  • Active comparator
    standard ACLS in refractory OHCA

    Emergency standard advanced cardiac life support ( ACLS ) in cardiopulmonary resuscitation of OHCA patients with refractory ventricular fibrillation or pulseless ventricular tachycardia. Bailout ECMO allowed after at least 45 minutes of CPR since collapse and 119 call or at least 15 minutes since arrival at emergency department

    Procedure: standard ACLS

Interventions

  • Procedureextracorporeal life support

    ECMO supported life support for cardiopulmonary resuscitation in refractory OHCA

  • Procedurestandard ACLS

    Standard ACLS in cardioplumonary resuscitation of refractory OHCA

06

What researchers measure

Primary outcomes

  1. The rate of survival with favorable neurological outcome ( modified Rankin score less than 3 or cerebral performance category scale 1 or 2 ) at 30 days after discharge from hospital, in percentage

    After survival discharge from hospital, clinical followup at out-patient clinic or by visual phone interview is conducted to assess medical health status as well as neurological status of the patients at 30 days after discharge from hospital. Survival with favorable neurological outcome ( i.e. modified Rankin score less than 3 or cerebral performance category scale 1 or 2 ) is to be measured as percentage of all randomized patients fulfilling inclusion criteria and without any exclusion criteria.

    Time frame: From randomization to 30 days after survival discharge from hospital

Secondary outcomes

  1. Total duration of cardioplumonary resuscitation from on-site CPR by EMS till the stable ROSC or initiation of ECMO life support or the decease of the subject at emergency department up to 30 days after randomization, in minutes

    total duration of standard cardiopulmonary resuscitation ( CPR ) is counted from the start of on-site CPR by emergency medical service ( EMS ) till the stable return of spontaneous circulation ( ROSC ) or initiation of ECMO life support or the decease of the subject at emergency department ( ED ) up to 30 days after randomization. The measure is in minutes.

    Time frame: From the start of on-site CPR by EMS till the return of stable ROSC or the initiation of ECMO life support or the decease of the subject at the emergency department up to 30 days after randomization, in minutes

  2. The rate of survival with favorable neurological outcome ( modified Rankin score less than 3 or CPC scale 1 or 2 ) from the date of randomization to the date of discharge from hospital up to 180 days after randomization, in percentage

    At discharge from hospital, patient status is assessed as survival or mortality. The rate of survival with favorable neurological outcome ( modified Rankin score \<3 or CPC scale 1 or 2 ) is counted from the date of randomization to the date of discharge from hospital up to 180 days after randomization. The rate of survival is measured as percentage of total randomization number.

    Time frame: From the date of randomization to the date of discharge from hospital up to 180 days after randomization, in percentage.

  3. The rate of survival with favorable outcomes ( modified Rankin score less than 3 or cerebral performance category scale 1 or 2 ) at 90 days after discharge from hospital, in percentage

    After patients survived and discharged from hospital, clinical followup at out-patient clinic or by visual phone interview is conducted to assess medical health as well as neurological status at 90 days after discharge. The rate of survival with favorable neurological outcome ( i.e. modified Rankin score less than 3 or cerebral performance category scale 1 or 2 ) is measured as percentage of all randomized patients fulfilling inclusion criteria and without any exclusion criteria.

    Time frame: From the date of randomization to 90 days after survival discharge from hospital

  4. The rate of survival with favorable outcomes ( modified Rankin score less than 3 or cerebral performance category scale 1 or 2 ) at 180 days, in percentage

    After patients discharged from hospital, clinical followup at out-patient clinic or by visual phone interview is conducted to assess medical health as well as neurological status at 180 days after discharge. The rate of survival with favorable neurological outcome ( i.e. modified Rankin score less than 3 or cerebral performance category scale 1 or 2 ) is measured as percentage of all enrolled patients fulfilling inclusion criteria and without any exclusion criteria.

    Time frame: From enrollment to the end of treatment at 180 days

  5. total duration of mechanical ventilation from randomization to discharge from hospital or up to 180 days after randomization , in days

    The total duration of assisted mechanical ventilation by volume cycle or pressure cycled artificial ventilators from randomization at the emergency department to discharge from hospital or up to 180 days after randomization, measured in days.

    Time frame: From randomization at the emergency department to discharge from hospital or up to 180 days after randomization

  6. total duration of stay in intensive care ward from randomization to discharge from hospital or up to 180 days after randomization , in days

    The total duration of stay in intensive care ward from randomization to discharge from hospital or up to 180 days after randomization. The intensive care ward is to provide cardiovascular hemodynamic support, assisted mechanical ventilation, targeted temperature therapy ( if needed ) and infection control, whenever needed. The measure is in days.

    Time frame: From the date of randomization to the date of discharge from hospital or up to 180 days after randomization

  7. total duration of hospitalization from the date of randomization to the date of discharge or up to 180 days after randomization , in days

    total duration of stay in the hospital from the date randomization at emergency department to the date discharge from hospital or up to 180 days after randomization, survived or deceased. The measure in in days.

    Time frame: From the date of randomization to the date of discharge from hospital or up to 180 days after randomization, survived or deceased.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Fu HY, Liu YH, Li SJ, Chang HC, Liu CC, Lee CM, Huang CY, Hsu CW, Ko CI, Wang YC, Chang WT, Wang TJ, Ong JR, Sun JT, Chen JS, Hsu CY, Jang SJ, Chen YL, Lin YH, Chien CY, Kung YC, Wang TL, Yu HC, Hsu CC, Chao CC, Chen CW, Hsu CY, Hsu SC, Chang TI, Yeh JS, Tsai MS, Wei LY, Chou HW, Wang CH, Chang CH, Chen CL, Tu YK, Lin JL, Chen YS. Emergency total extracorporeal life support versus standard advanced cardiac life support with rescue extracorporeal membrane oxygenation for refractory out-of-hospital cardiac arrest: protocol for the ECLS-OHCA randomized trial. Scand J Trauma Resusc Emerg Med. 2026 Feb 3;34(1):53. doi: 10.1186/s13049-026-01557-w. PubMed 41630056 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2028, 48 months after the start.

Of 93 non-industry interventional studies with no phase under Out-of-Hospital Cardiac Arrest, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 48 months is above that.

Counting every sponsor, half of 95 studies reached it within 34 months; a quarter within 19 and three quarters within 57.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Nov 2027 → Nov 2028 and completion Nov 2027 → Jul 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2024
First posted
Nov 18, 2024
StartActual
Nov 1, 2024
Primary completionEst.
Nov 2028was Nov 2027
CompletionEst.
Jul 2029was Nov 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 9, 2026
Sites
2 sites added, 1 site removed
Show 2 added (2 Taiwan)
  • Shuang Ho Hospital · New Taipei, Taiwan
  • Shuang Ho Hospital · New Taipei, Taiwan
Show 1 removed
  • Shuang Ho Hospital · New Taipei, Taiwan
Nov 9, 2026
Primary completion
Nov 2027→Nov 2028
Nov 9, 2026
Study completion
Nov 2027→Jul 2029
Nov 9, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41630056 ↗
Nov 9, 2026
Contact
Study contact now listed: added j•••@gmail.com · •••2589. See the current contact
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Active, not recruiting→Recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41630056 ↗
    2 sites added, 1 site removed
    Show 2 added (2 Taiwan)
    • Shuang Ho Hospital · New Taipei, Taiwan
    • Shuang Ho Hospital · New Taipei, Taiwan
    Show 1 removed
    • Shuang Ho Hospital · New Taipei, Taiwan
    Primary completion Nov 2027→Nov 2028
    Study completion Nov 2027→Jul 2029
    Contact Study contact now listed: added j•••@gmail.com · •••2589. See the current contact
    + 3 other changes: verification date, responsible party and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06692075
Collaborators
Far Eastern Memorial Hospital, Taichung Tzu Chi Hospital, National Taiwan University Hospital, Taipei Medical University Hospital, Taipei Medical University WanFang Hospital, Fu Jen Catholic University Hospital, Mackay Memorial Hospital, Chiba University Hospital, Japan, Taipei Hospital, Taiwan
Responsible party
Sponsor
First posted
Nov 18, 2024
Start date
Nov 1, 2024
Primary completion
Nov 2028 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Jiunn-Lee Lin, MD, PHD
Contact
jiunnleelin@gmail.com
+886-66202589 ext. 15313

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion